IMPROVE HEALTH OUTCOMES

AbbVie believes that the world needs new approaches to addressing today’s health challenges. We will go beyond the medicine to deliver innovative, holistic healthcare solutions to patients. We commit to target unmet needs to support patients and enhance access to healthcare across geographies.

As part of our patient-first approach, AbbVie is passionate about developing solutions to meet patient needs around the world.

AbbVie expands access to medication by supporting U.S. patient assistance programs that provide free medication to eligible patients. In 2014, AbbVie Patient Assistance Foundation helped nearly 111,000 patients.

In 2014, AbbVie and the Medicines Patent Pool signed a new agreement that will increase access to HIV treatment and improve the lives of children living with the disease.

With the support of AbbVie, the Partnership for Prescription Assistance (PPA) offers a single point of access to information on 475 public and private patient assistance programs, including nearly 200 programs offered by pharmaceutical companies. Since launch, the PPA has connected nearly 9.5 million people to patient assistance programs that may meet their needs.

AbbVie partners with HarborPath to provide free anti-retroviral medications to uninsured patients in the U.S. including those eligible for the AIDS Drug Assistance Program but not able to access medication due to state funding limits.

Pharmacy Solutions, an AbbVie pharmacy in the U.S., strives to improve patient treatment outcomes by working with healthcare providers, patients and payers to improve health via access to medications, pharmacy services and care management solutions. Pharmacy Solutions is the first biopharmaceutical company-owned specialty pharmacy to receive accreditation status by Accreditation Commission for Health Care (ACHC) for the services of Specialty Pharmacy and Durable Medical Equipment Service (DMEPOS) in 2013.

AbbVie partners and collaborates with others to build health system capacity and infrastructure to increase access to care. We aim to leverage our history working with partners to build health care capacity globally.

AbbVie and AbbVie Foundation provide critically-needed medicine and grants to humanitarian relief partners to help those affected by natural disasters and to strengthen health systems. Following the 2015 Nepal earthquake, we provided $650,000 in medicines and cash grants to humanitarian relief partners. In 2014, AbbVie and the AbbVie Foundation provided $2.1 million in medicines and cash grants to respond to six disasters, including support to combat the Ebola virus.

The AbbVie Foundation has supported the distribution of 27 million HIV rapid tests in 15 countries, in partnership with Direct Relief, to help prevent the spread of HIV/AIDS from mothers to infants.

AbbVie and the AbbVie Foundation’s support for Academic Model Providing Access To Healthcare (AMPATH) has helped build an innovative home-based HIV testing and counselling program in East Africa, reaching more than one million people.

AbbVie partners with the Philippines Society of Newborn Medicine and government agencies to strengthen local capacity and reduce prevalence of Respiratory Distress Syndrome (RDS), the second leading cause of infant mortality in the country. Together we’re creating a national registry to track disease rates, a crucial first step in controlling RDS.

Across Europe, AbbVie is working with stakeholders to address the changing disease burden and promote more effective and sustainable health care systems. Our Sustainable Healthcare initiative convenes academia, healthcare providers, patients' groups and industry to find solutions to improve patient care while reducing costs.

AbbVie is committed to supporting programs aimed at increasing the understanding of scientific, clinical and healthcare issues that improve patient care. We partner with a broad range of organizations to help address today’s healthcare challenges to ensure that patients, and the healthcare providers who treat them, receive information and support needed. In 2014 AbbVie provided 617 medical education grants in 39 disease states to organizations in the United States.

Continuing education is critical to ensuring the best treatment is accompanied by the right knowledge to fully meet the needs of patients. We offer programs and opportunities for healthcare professionals in support of medical and patient education. AbbVie Grant Management supports appropriate third-party entities, including healthcare delivery organizations and professional associations, to foster increased understanding of scientific, clinical or healthcare issues that contribute to the enhancement of patient care. AbbVie also supports charitable donation requests from non-profit organizations, including non-profit healthcare providers.

The reports below disclose charitable donations, educational grants, fellowships and scholarships, patient support and corporate sponsorships. Recipients include medical and other healthcare professional organizations, patient organizations, academic institutions, hospitals, medical education companies and other scientific associations. All AbbVie grant requests originating from the U.S. and Puerto Rico are processed by a centralized grant management department. In addition, support from the non-profit, philanthropic AbbVie Foundation will be reported in an annual Internal Revenue Service 990-PF filing. This information is available on www.foundationcenter.org.

The posted reports include individual direct payments of more than $200 from Abbvie’s U.S. and Puerto Rico businesses. The reports may be updated periodically to reflect new data.

Grants & Donations Report

2012            
3rd Quarter 
|  4th Quarter        
             
2013            
1st Quarter   |  2nd Quarter    |  3rd Quarter    |  4th Quarter
             
2014            
Annual             

AbbVie aims to leverage our expertise and resources to address global health needs and improve standards of care. Research and innovation are the cornerstones of AbbVie's business as a global biopharmaceutical company. Our research and innovation focus on developing medicines that deliver strong clinical performance, provide more patient benefit and deliver economic value, particularly where there is significant need around the world in certain disease areas. These areas include immunology, kidney disease, liver disease, neuroscience, oncology and women’s health. We also work with healthcare professionals primarily in the research and development process and in medical education. Their expertise helps us develop and enhance products and therapies to treat conditions including HIV, arthritis, immunological and metabolic disorders, heart disease, and cancer. Their collaboration helps to improve existing products and deliver innovation in patient care that has been the hallmark of medical advancement. Our interactions with healthcare professionals during the development process are essential to providing patients with products that are backed by extensive clinical experience.

In addition, we work to address neglected tropical diseases (NTDs), infections that disproportionately impact the world's poor and marginalized populations. According to the World Health Organization, more than 1 billion people suffer from one or more of these conditions. More than 100 of AbbVie’s most experienced scientists are collaborating with partners on drug development projects, advisory boards and compound screening to help solve NTDs. Learn more about our NTD partners.

YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE

Notice

The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?

EXIT ABBVIE.COM

The product-specific site Internet site that you have requested is intended for the residents of a particular country or countries, as noted on that site.

As a result, the site may contain information on pharmaceuticals that are not approved in other countries or region. If you are a resident of a country other than those to which the site is directed, please return to AbbVie.com or contact your local AbbVie affiliate to obtain the appropriate product information for your country of residence.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to continue to this product-specific site?

YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE

Notice

The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?